Oral fingolimod (FTY720) in relapsing multiple sclerosis : impact on health-related quality of life in a phase II study

Date Issued
2011-01-01
Author(s)
Montalban, X.
Comi, G.
O'Connor, P.
Gold, Sm
de Vera, A.
Eckert, B.
DOI
10.1177/1352458511411061
Abstract
Health-related quality of life (HRQoL) worsens with multiple sclerosis (MS) relapses and disease progression. Common symptoms including depression and fatigue may contribute to poor HRQoL.